Hope vs. Power: Gene Therapy, FDA Shake-Up, and Truth in Medicine

Send us Fan MailSend us a textOriginal Substack Release: Aug 23, 2025🎯 Why ListenWhen hope collides with billion-dollar incentives, who protects patients? We unpack Vinay Prasad’s FDA resignation, Sarepta’s $3.2M Duchenne gene therapy, and how accelerated approvals can leave families without the long-term data they deserve.👥 Co-HostsDutch Rojas – Founder, Bliksem HealthAnthony DiGiorgio, DO, MHA – Neurosurgeon, UCSF; health policy researcherAnish Koka, MD – Cardiologist, Philadelphia; healthcare policy commentatorDan Choi, MD, FAAOS – Orthopedic spine surgeon, Long Island; healthcare advocate and social media voiceSanat Dixit, MD, FACS – Neurosurgeon, Huntsville, AL; Faculty, Vanderbilt University; healthcare entrepreneur📌 Episode OverviewVinay Prasad’s exit from FDA/CBER and what it signals about evidence, safety, and politics.Duchenne muscular dystrophy, Sarepta’s one-shot gene therapy, and deaths linked to vector toxicity.The promise and peril of accelerated approvals—and why confirmatory trials so often stall.Left vs. right myths about healthcare; markets, incentives, and why “healthcare is a right” can fail in practice.Quick hits: public-good economics in medicine, decentralization vs. central control, and where AI may actually help (RCM, workflow).💬 Notable Quotes“These trials are never gonna get done. It’s a game—with patients as pawns.”“The FDA is the Midas touch: approval turns hope into revenue—fast.”“You don’t want a world where healthcare is non-excludable and non-rivalrous.”“If healthcare is ‘first, do no harm,’ who decides what harm looks like—and who pays the price?”📚 What You’ll LearnHow accelerated approval works—and where it breaks.Why safety signals (e.g., vector-related liver failure) matter more than press releases.The difference between hope, evidence, and incentives in rare disease.How political tribes systematically misunderstand healthcare mechanics.Practical places AI can improve care operations today.⏱ The Episode (Timestamps)00:00–01:10 Welcome back & cadence update (new Sunday drops)01:10–07:40 Vinay Prasad resigns from FDA/CBER—context and stakes07:40–13:30 Duchenne 101, dystrophin biology, trial endpoints vs. real outcomes13:30–17:30 Accelerated approval promises vs. missing confirmatory trials17:30–22:30 Safety signals: vector immunogenicity, reported deaths, what pulls look like22:30–28:30 Media/influencer pressure and the politics of “right to try”28:30–41:30 Is healthcare a public good? Scarcity, incentives, and economic reality41:30–50:30 Government, morality, and why central planning fails patients50:30–59:30 AI, agents, and near-term wins in physician workflows59:30–End What we need next from policymakers—and from clinicians🔗 Connect with the Hosts: • Dutch Rojas on X • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X🔗 Connect with the Hosts:• Dutch Rojas on X• Dr. Anthony DiGiorgio on X• Dr. Anish Koka on X• Dr. Dan Choi on X• Dr. Sanat Dixit on X